Skip to content
2000
Volume 26, Issue 3
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Breast cancer is the most prevalent malignant tumor among women globally, with breast cancer susceptibility genes (BRCA1 and BRCA2, BRCA1/2) mutations significantly increasing the risk of developing aggressive forms of the disease. Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have shown promise in treating BRCA1/2-mutated breast cancer by exploiting deficiencies in homologous recombination (HR) repair. However, the emergence of acquired resistance poses a significant challenge. Our study examines the mechanisms of PARPi resistance in BRCA1/2-mutated breast cancer, synthesizing recent clinical advancements and identifying key resistance pathways, including HR recovery, DNA replication fork stability, and epigenetic modifications. We also highlight potential strategies to overcome these challenges to PARPi resistance, such as combination therapies and novel targets. Our comprehensive analysis aims to inform future clinical practices and guide the development of more effective treatment strategies.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206381898250428064533
2025-05-06
2026-03-06

  • From This Site

    /content/journals/acamc/10.2174/0118715206381898250428064533
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SungH. FerlayJ. SiegelR.L. LaversanneM. SoerjomataramI. JemalA. BrayF. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.202171320924910.3322/caac.21660 33538338
     [Google Scholar]
  2. The cancer genome atlas network. Comprehensive molecular portraits of human breast tumours.Nature20124907418617010.1038/nature11412 23000897
     [Google Scholar]
  3. KuchenbaeckerK.B. HopperJ.L. BarnesD.R. PhillipsK.A. MooijT.M. Roos-BlomM.J. JervisS. van LeeuwenF.E. MilneR.L. AndrieuN. GoldgarD.E. TerryM.B. RookusM.A. EastonD.F. AntoniouA.C. McGuffogL. EvansD.G. BarrowdaleD. FrostD. AdlardJ. OngK. IzattL. TischkowitzM. EelesR. DavidsonR. HodgsonS. EllisS. NoguesC. LassetC. Stoppa-LyonnetD. FrickerJ.P. FaivreL. BerthetP. HooningM.J. van der KolkL.E. KetsC.M. AdankM.A. JohnE.M. ChungW.K. AndrulisI.L. SoutheyM. DalyM.B. BuysS.S. OsorioA. EngelC. KastK. SchmutzlerR.K. CaldesT. JakubowskaA. SimardJ. FriedlanderM.L. McLachlanS.A. MachackovaE. ForetovaL. TanY.Y. SingerC.F. OlahE. GerdesA.M. ArverB. OlssonH. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.JAMA2017317232402241610.1001/jama.2017.7112 28632866
     [Google Scholar]
  4. EversB. HelledayT. JonkersJ. Targeting homologous recombination repair defects in cancer.Trends Pharmacol. Sci.201031837238010.1016/j.tips.2010.06.001 20598756
     [Google Scholar]
  5. RemonJ. BesseB. LearyA. BiècheI. JobB. LacroixL. AugusteA. MauduitM. Audigier-ValetteC. RaimbourgJ. MadroszykA. MichelsS. BayarM.A. JimenezM. SoriaJ.C. RouleauE. BarlesiF. Somatic and germline BRCA 1 and 2 mutations in advanced NSCLC from the SAFIR02-lung trial.JTO Clin. Res. Rep.20201310006810.1016/j.jtocrr.2020.100068 34589950
     [Google Scholar]
  6. OhmotoA. YachidaS. Current status of poly(ADP-ribose) polymerase inhibitors and future directions.OncoTargets Ther.2017105195520810.2147/OTT.S139336 29138572
     [Google Scholar]
  7. Sánchez-OleaR. CaleraM.R. DegterevA. Molecular pathways involved in cell death after chemically induced DNA damage.EXS20099920923010.1007/978‑3‑7643‑8336‑7_8 19157063
     [Google Scholar]
  8. D’AndreaA.D. Mechanisms of PARP inhibitor sensitivity and resistance.DNA Repair20187117217610.1016/j.dnarep.2018.08.021 30177437
     [Google Scholar]
  9. GuleriaM. KumarP. TharejaS. Synthetic PARP-1 inhibitors reported during the last decade.Lett. Drug Des. Discov.202320779380710.2174/1570180819666220615090709
     [Google Scholar]
  10. VermaS. PathaniaA.S. BaranwalS. KumarP. Synthesis and in silico studies of quinazolinone derivatives as PARP-1 inhibitors.Lett. Drug Des. Discov.202017121552156510.2174/1570180817999200719152959
     [Google Scholar]
  11. RobsonM. ImS.A. SenkusE. XuB. DomchekS.M. MasudaN. DelalogeS. LiW. TungN. ArmstrongA. WuW. GoesslC. RunswickS. ConteP. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation.N. Engl. J. Med.2017377652353310.1056/NEJMoa1706450 28578601
     [Google Scholar]
  12. RobsonM.E. TungN. ConteP. ImS.A. SenkusE. XuB. MasudaN. DelalogeS. LiW. ArmstrongA. WuW. GoesslC. RunswickS. DomchekS.M. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.Ann. Oncol.201930455856610.1093/annonc/mdz012 30689707
     [Google Scholar]
  13. EustermannS. WuW.F. LangelierM.F. YangJ.C. EastonL.E. RiccioA.A. PascalJ.M. NeuhausD. Structural basis of detection and signaling of DNA single-strand breaks by human PARP-1.Mol. Cell201560574275410.1016/j.molcel.2015.10.032 26626479
     [Google Scholar]
  14. SchreiberV. DantzerF. AmeJ.C. De MurciaG. Poly(ADP-ribose): Novel functions for an old molecule.Nat. Rev. Mol. Cell Biol.20067751752810.1038/nrm1963 16829982
     [Google Scholar]
  15. ZielińskaZ. OłdakŁ. GorodkiewiczE. Methods of PARP-1 determination and its importance in living organisms.Protein Pept. Lett.202229649650410.2174/0929866529666220405160715 35382713
     [Google Scholar]
  16. De VosM. SchreiberV. DantzerF. The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art.Biochem. Pharmacol.201284213714610.1016/j.bcp.2012.03.018 22469522
     [Google Scholar]
  17. CurtinN.J. SzaboC. Poly(ADP-ribose) polymerase inhibition: Past, present and future.Nat. Rev. Drug Discov.2020191071173610.1038/s41573‑020‑0076‑6 32884152
     [Google Scholar]
  18. RayC.A. NussenzweigA. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling.Nat. Rev. Mol. Cell Biol.2017181061062110.1038/nrm.2017.53 28676700
     [Google Scholar]
  19. AlemasovaE.E. LavrikO.I. Poly(ADP-ribosyl)ation by PARP1: Reaction mechanism and regulatory proteins.Nucleic Acids Res.20194783811382710.1093/nar/gkz120 30799503
     [Google Scholar]
  20. KeungM. WuY. VadgamaJ. PARP inhibitors as a therapeutic agent for homologous recombination deficiency in breast cancers.J. Clin. Med.20198443510.3390/jcm8040435 30934991
     [Google Scholar]
  21. Sadakierska-ChudyA. FilipM. A comprehensive view of the epigenetic landscape. Part II: Histone post-translational modification, nucleosome level, and chromatin regulation by ncRNAs.Neurotox. Res.201527217219710.1007/s12640‑014‑9508‑6 25516120
     [Google Scholar]
  22. BrownJ.S. O’CarriganB. JacksonS.P. YapT.A. Targeting DNA repair in cancer: Beyond PARP inhibitors.Cancer Discov.201771203710.1158/2159‑8290.CD‑16‑0860 28003236
     [Google Scholar]
  23. WatanabeK. SekiN. Biology and development of DNA-targeted drugs, focusing on synthetic lethality, DNA repair, and epigenetic modifications for cancer: A review.Int. J. Mol. Sci.202425275210.3390/ijms25020752 38255825
     [Google Scholar]
  24. AshworthA. LordC.J. Synthetic lethal therapies for cancer: What’s next after PARP inhibitors?Nat. Rev. Clin. Oncol.201815956457610.1038/s41571‑018‑0055‑6 29955114
     [Google Scholar]
  25. TuttA.N.J. GarberJ.E. KaufmanB. VialeG. FumagalliD. RastogiP. GelberR.D. de AzambujaE. FieldingA. BalmañaJ. DomchekS.M. GelmonK.A. HollingsworthS.J. KordeL.A. LinderholmB. BandosH. SenkusE. SugaJ.M. ShaoZ. PippasA.W. NoweckiZ. HuzarskiT. GanzP.A. LucasP.C. BakerN. LoiblS. McConnellR. PiccartM. SchmutzlerR. StegerG.G. CostantinoJ.P. ArahmaniA. WolmarkN. McFaddenE. KarantzaV. LakhaniS.R. YothersG. CampbellC. GeyerC.E. Adjuvant olaparib for patients with BRCA1 - or BRCA2 -Mutated breast cancer.N. Engl. J. Med.2021384252394240510.1056/NEJMoa2105215 34081848
     [Google Scholar]
  26. GradisharW.J. MoranM.S. AbrahamJ. AftR. AgneseD. AllisonK.H. BlairS.L. BursteinH.J. DangC. EliasA.D. GiordanoS.H. GoetzM.P. GoldsteinL.J. HurvitzS.A. IsakoffS.J. JankowitzR.C. JavidS.H. KrishnamurthyJ. LeitchM. LyonsJ. MatroJ. MayerI.A. MortimerJ. O’ReganR.M. PatelS.A. PierceL.J. RugoH.S. SitapatiA. SmithK.L. SmithM.L. SolimanH. Stringer-ReasorE.M. TelliM.L. WardJ.H. WisinskiK.B. YoungJ.S. BurnsJ.L. KumarR. NCCN Guidelines® Insights: Breast Cancer, Version 4.2021.J. Natl. Compr. Canc. Netw.202119548449310.6004/jnccn.2021.0023 34794122
     [Google Scholar]
  27. Nader-MartaG. MolinelliC. DebienV. Martins-BrancoD. AftimosP. de AzambujaE. AwadaA. Antibody–drug conjugates: The evolving field of targeted chemotherapy for breast cancer treatment.Ther. Adv. Med. Oncol.2023151758835923118367910.1177/17588359231183679 37435563
     [Google Scholar]
  28. PopovicL.S. Matovina-BrkoG. PopovicM. PunieK. CvetanovicA. LambertiniM. Targeting triple-negative breast cancer: A clinical perspective.Oncol. Res.202331322123810.32604/or.2023.028525 37305385
     [Google Scholar]
  29. SciarraA. SantarelliV. SantodiroccoL. FrisendaM. SalcicciaS. CasaleP. ForteF. MariottiG. MoriconiM. CattarinoS. SciarraB. BevilacquaG. GentilucciA. Is it time to anticipate the use of PARP inhibition in prostate cancer patients?Curr. Oncol.20233098054806710.3390/curroncol30090584 37754499
     [Google Scholar]
  30. JerezY. Márquez-RodasI. AparicioI. AlvaM. MartínM. López-TarruellaS. Poly (ADP-ribose) polymerase inhibition in patients with breast cancer and BRCA 1 and 2 mutations.Drugs202080213114610.1007/s40265‑019‑01235‑5 31823331
     [Google Scholar]
  31. GelmonK.A. FaschingP.A. CouchF.J. BalmañaJ. DelalogeS. Labidi-GalyI. BennettJ. McCutcheonS. WalkerG. O’ShaughnessyJ. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: Phase IIIb LUCY interim analysis.Eur. J. Cancer2021152687710.1016/j.ejca.2021.03.029 34087573
     [Google Scholar]
  32. EttlJ. QuekR.G.W. LeeK.H. RugoH.S. HurvitzS. GonçalvesA. FehrenbacherL. YerushalmiR. MinaL.A. MartinM. RochéH. ImY.H. MarkovaD. BhattacharyyaH. HannahA.L. EiermannW. BlumJ.L. LittonJ.K. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: Patient-reported outcomes from the EMBRACA phase III trial.Ann. Oncol.20182991939194710.1093/annonc/mdy257 30124753
     [Google Scholar]
  33. TurnerN.C. BalmañaJ. PoncetC. GouliotiT. TryfonidisK. HonkoopA.H. ZoppoliG. RazisE. JohannssonO.T. ColleoniM. TuttA.N. AudehW. IgnatiadisM. MailliezA. TrédanO. MusolinoA. VuylstekeP. Juan-FitaM.J. MacphersonI.R.J. KaufmanB. MansoL. GoldsteinL.J. EllardS.L. LángI. JenK.Y. AdamV. LitièreS. ErbanJ. CameronD.A. Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 Mutations: The EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO study.Clin. Cancer Res.202127205482549110.1158/1078‑0432.CCR‑21‑0310 34301749
     [Google Scholar]
  34. SunT. ShiY. CuiJ. YinY. OuyangQ. LiuQ. ZhangQ. ChenY. ZhiminS. WangS. WangX. TongZ. ZhongY. YanM. YanX. WangC. YangH. LiM. XiangX. XuB. A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation.J. Clin. Oncol.20213915_suppl10871087Suppl.10.1200/JCO.2021.39.15_suppl.1087
     [Google Scholar]
  35. DiérasV. HanH.S. KaufmanB. WildiersH. FriedlanderM. AyoubJ.P. PuhallaS.L. BondarenkoI. CamponeM. JakobsenE.H. JalvingM. OpreanC. PalácováM. ParkY.H. ShparykY. YañezE. KhandelwalN. KunduM.G. DudleyM. RatajczakC.K. MaagD. ArunB.K. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): A randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol.202021101269128210.1016/S1470‑2045(20)30447‑2 32861273
     [Google Scholar]
  36. MouwK.W. D’AndreaA.D. DNA repair deficiency and immunotherapy response.J. Clin. Oncol.201836171710171310.1200/JCO.2018.78.2425 29683789
     [Google Scholar]
  37. VinayakS. TolaneyS.M. SchwartzbergL. MitaM. McCannG. TanA.R. Wahner-HendricksonA.E. ForeroA. AndersC. WulfG.M. DillonP. LynceF. ZarwanC. ErbanJ.K. ZhouY. BuerstatteN. GrahamJ.R. AroraS. DezubeB.J. TelliM.L. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer.JAMA Oncol.2019581132114010.1001/jamaoncol.2019.1029 31194225
     [Google Scholar]
  38. WaksA.G. CohenO. KochupurakkalB. KimD. DunnC.E. Buendia BuendiaJ. WanderS. HelvieK. LloydM.R. MariniL. HughesM.E. FreemanS.S. IvyS.P. GeradtsJ. IsakoffS. LoRussoP. AdalsteinssonV.A. TolaneyS.M. MatulonisU. KropI.E. D’AndreaA.D. WinerE.P. LinN.U. ShapiroG.I. WagleN. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.Ann. Oncol.202031559059810.1016/j.annonc.2020.02.008 32245699
     [Google Scholar]
  39. FongP.C. BossD.S. YapT.A. TuttA. WuP. Mergui-RoelvinkM. MortimerP. SwaislandH. LauA. O’ConnorM.J. AshworthA. CarmichaelJ. KayeS.B. SchellensJ.H.M. de BonoJ.S. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.N. Engl. J. Med.2009361212313410.1056/NEJMoa0900212 19553641
     [Google Scholar]
  40. FongP.C. YapT.A. BossD.S. CardenC.P. Mergui-RoelvinkM. GourleyC. De GreveJ. LubinskiJ. ShanleyS. MessiouC. A’HernR. TuttA. AshworthA. StoneJ. CarmichaelJ. SchellensJ.H.M. de BonoJ.S. KayeS.B. Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.J. Clin. Oncol.201028152512251910.1200/JCO.2009.26.9589 20406929
     [Google Scholar]
  41. DiasM.P. MoserS.C. GanesanS. JonkersJ. Understanding and overcoming resistance to PARP inhibitors in cancer therapy.Nat. Rev. Clin. Oncol.2021181277379110.1038/s41571‑021‑00532‑x 34285417
     [Google Scholar]
  42. RottenbergS. JaspersJ.E. KersbergenA. van der BurgE. NygrenA.O.H. ZanderS.A.L. DerksenP.W.B. De BruinM. ZevenhovenJ. LauA. BoulterR. CranstonA. O’ConnorM.J. MartinN.M.B. BorstP. JonkersJ. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.Proc. Natl. Acad. Sci. USA200810544170791708410.1073/pnas.0806092105 18971340
     [Google Scholar]
  43. ChenZ. LingK. ZhuY. DengL. LiY. LiangZ. Rucaparib antagonize multidrug resistance in cervical cancer cells through blocking the function of ABC transporters.Gene202075914500010.1016/j.gene.2020.145000 32717310
     [Google Scholar]
  44. van HoppeS. SparidansR.W. WagenaarE. BeijnenJ.H. SchinkelA.H. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation.Pharmacol. Res.2017120435010.1016/j.phrs.2017.01.035 28288939
     [Google Scholar]
  45. ChristieE.L. PattnaikS. BeachJ. CopelandA. RashooN. FeredayS. HendleyJ. AlsopK. BradyS.L. LambG. PandeyA. deFazioA. ThorneH. BildA. BowtellD.D.L. Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer.Nat. Commun.2019101129510.1038/s41467‑019‑09312‑9 30894541
     [Google Scholar]
  46. TurkA.A. WisinskiK.B. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.Cancer2018124122498250610.1002/cncr.31307 29660759
     [Google Scholar]
  47. WangY.Q. WangP.Y. WangY.T. YangG.F. ZhangA. MiaoZ.H. An update on poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors: Opportunities and challenges in cancer therapy.J. Med. Chem.201659219575959810.1021/acs.jmedchem.6b00055 27416328
     [Google Scholar]
  48. ShenY. Aoyagi-ScharberM. WangB. Trapping Poly(ADP-Ribose).Polymerase. J. Pharmacol. Exp. Ther.2015353344645710.1124/jpet.114.222448 25758918
     [Google Scholar]
  49. MuraiJ. HuangS.Y.N. RenaudA. ZhangY. JiJ. TakedaS. MorrisJ. TeicherB. DoroshowJ.H. PommierY. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.Mol. Cancer Ther.201413243344310.1158/1535‑7163.MCT‑13‑0803 24356813
     [Google Scholar]
  50. NoordermeerS.M. Van AttikumH. PARP inhibitor resistance: A tug-of-war in BRCA-mutated cells.Trends Cell Biol.2019291082083410.1016/j.tcb.2019.07.008 31421928
     [Google Scholar]
  51. MinA. Im, S.A. PARP inhibitors as therapeutics: Beyond modulation of PARylation.Cancers202012239410.3390/cancers12020394 32046300
     [Google Scholar]
  52. GogolaE. DuarteA.A. De RuiterJ.R. WiegantW.W. SchmidJ.A. de BruijnR. JamesD.I. Guerrero LlobetS. VisD.J. AnnunziatoS. van den BroekB. BarazasM. KersbergenA. van de VenM. TarsounasM. OgilvieD.J. Van VugtM. WesselsL.F.A. BartkovaJ. GromovaI. Andújar-SánchezM. BartekJ. LopesM. van AttikumH. BorstP. JonkersJ. RottenbergS. Selective loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality.Cancer Cell201833610781093.e1210.1016/j.ccell.2018.05.008 29894693
     [Google Scholar]
  53. AnaghoH.A. MullariM. PrószA.G. Buch-LarsenS.C. ChoH. Locard-PauletM. SzallasiZ. NielsenM.L. ADP-ribosylome analysis reveals homogeneous DNA-damage-induced serine ADP-ribosylation across wild-type and BRCA-mutant breast cancer cell lines.Cell Rep.202443711443310.1016/j.celrep.2024.114433 38985679
     [Google Scholar]
  54. GornsteinE.L. SandefurS. ChungJ.H. GayL.M. HolmesO. ErlichR.L. SomanS. MartinL.K. RoseA.V. StephensP.J. RossJ.S. MillerV.A. AliS.M. BlauS. BRCA2 reversion mutation associated with acquired resistance to olaparib in estrogen receptor-positive breast cancer detected by genomic profiling of tissue and liquid biopsy.Clin. Breast Cancer201818218418810.1016/j.clbc.2017.12.010 29325860
     [Google Scholar]
  55. GoodallJ. MateoJ. YuanW. MossopH. PortaN. MirandaS. Perez-LopezR. DollingD. RobinsonD.R. SandhuS. FowlerG. EbbsB. FlohrP. SeedG. RodriguesD.N. BoysenG. BertanC. AtkinM. ClarkeM. CrespoM. FigueiredoI. RiisnaesR. SumanasuriyaS. RescignoP. ZafeiriouZ. SharpA. TunariuN. BianchiniD. GillmanA. LordC.J. HallE. ChinnaiyanA.M. CarreiraS. de BonoJ.S. Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition.Cancer Discov.2017791006101710.1158/2159‑8290.CD‑17‑0261 28450425
     [Google Scholar]
  56. ZhengF. ZhangY. ChenS. WengX. RaoY. FangH. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.Biomed. Pharmacother.202012310966110.1016/j.biopha.2019.109661 31931287
     [Google Scholar]
  57. FrancicaP. RottenbergS. Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response.Genome Med.201810110110.1186/s13073‑018‑0612‑8 30593284
     [Google Scholar]
  58. Escribano-DíazC. OrthweinA. Fradet-TurcotteA. XingM. YoungJ.T.F. TkáčJ. CookM.A. RosebrockA.P. MunroM. CannyM.D. XuD. DurocherD. A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice.Mol. Cell201349587288310.1016/j.molcel.2013.01.001 23333306
     [Google Scholar]
  59. NoordermeerS.M. AdamS. SetiaputraD. BarazasM. PettittS.J. LingA.K. OlivieriM. Álvarez-QuilónA. MoattiN. ZimmermannM. AnnunziatoS. KrastevD.B. SongF. BrandsmaI. FrankumJ. BroughR. SherkerA. LandryS. SzilardR.K. MunroM.M. McEwanA. Goullet de RugyT. LinZ.Y. HartT. MoffatJ. GingrasA.C. MartinA. van AttikumH. JonkersJ. LordC.J. RottenbergS. DurocherD. The shieldin complex mediates 53BP1-dependent DNA repair.Nature2018560771611712110.1038/s41586‑018‑0340‑7 30022168
     [Google Scholar]
  60. XuG. ChapmanJ.R. BrandsmaI. YuanJ. MistrikM. BouwmanP. BartkovaJ. GogolaE. WarmerdamD. BarazasM. JaspersJ.E. WatanabeK. PieterseM. KersbergenA. SolW. CelieP.H.N. SchoutenP.C. Van den BroekB. SalmanA. NieuwlandM. de RinkI. de RondeJ. JalinkK. BoultonS.J. ChenJ. van GentD.C. BartekJ. JonkersJ. BorstP. RottenbergS. REV7 counteracts DNA double-strand break resection and affects PARP inhibition.Nature2015521755354154410.1038/nature14328 25799992
     [Google Scholar]
  61. GhezraouiH. OliveiraC. BeckerJ.R. BilhamK. MoralliD. AnzilottiC. FischerR. Deobagkar-LeleM. Sanchiz-CalvoM. Fueyo-MarcosE. BonhamS. KesslerB.M. RottenbergS. CornallR.J. GreenC.M. ChapmanJ.R. 53BP1 cooperation with the REV7–shieldin complex underpins DNA structure-specific NHEJ.Nature2018560771612212710.1038/s41586‑018‑0362‑1 30046110
     [Google Scholar]
  62. Ray ChaudhuriA. CallenE. DingX. GogolaE. DuarteA.A. LeeJ.E. WongN. LafargaV. CalvoJ.A. PanzarinoN.J. JohnS. DayA. CrespoA.V. ShenB. StarnesL.M. RuiterJ.R. DanielJ.A. KonstantinopoulosP.A. CortezD. CantorS.B. Fernandez-CapetilloO. GeK. JonkersJ. RottenbergS. SharanS.K. NussenzweigA. Replication fork stability confers chemoresistance in BRCA-deficient cells.Nature2016535761238238710.1038/nature18325 27443740
     [Google Scholar]
  63. HeY.J. MeghaniK. CaronM.C. YangC. RonatoD.A. BianJ. SharmaA. MooreJ. NirajJ. DetappeA. DoenchJ.G. LegubeG. RootD.E. D’AndreaA.D. DranéP. DeS. KonstantinopoulosP.A. MassonJ.Y. ChowdhuryD. DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells.Nature2018563773252252610.1038/s41586‑018‑0670‑5 30464262
     [Google Scholar]
  64. ParmarK. KochupurakkalB.S. LazaroJ.B. WangZ.C. PalakurthiS. KirschmeierP.T. YangC. SambelL.A. FärkkiläA. ReznichenkoE. ReavisH.D. DunnC.E. ZouL. DoK.T. KonstantinopoulosP.A. MatulonisU.A. LiuJ.F. D’AndreaA.D. ShapiroG.I. The CHK1 inhibitor prexasertib exhibits monotherapy activity in high-grade serous ovarian cancer models and sensitizes to PARP inhibition.Clin. Cancer Res.201925206127614010.1158/1078‑0432.CCR‑19‑0448 31409614
     [Google Scholar]
  65. TaglialatelaA. AlvarezS. LeuzziG. SanninoV. RanjhaL. HuangJ.W. MadubataC. AnandR. LevyB. RabadanR. CejkaP. CostanzoV. CicciaA. Restoration of replication fork stability in BRCA1- and BRCA2-deficient cells by inactivation of SNF2-family fork remodelers.Mol. Cell2017682414430.e810.1016/j.molcel.2017.09.036 29053959
     [Google Scholar]
/content/journals/acamc/10.2174/0118715206381898250428064533
Loading
Unraveling the Resistance: Challenges and Advances in PARP Inhibitor Therapy for BRCA1/2 Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry 26, 268 (2026); https://doi.org/10.2174/0118715206381898250428064533
/content/journals/acamc/10.2174/0118715206381898250428064533
/content/journals/acamc/10.2174/0118715206381898250428064533
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): BRCA1; BRCA2; Breast cancer; combination therapies; drug resistance; PARP inhibitor

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test